Abstract:In humans, dual-specificity Tyrosine-Phosphorylation-Regulated Kinase 1A is an enzyme encoded by the DYRK1A gene involved in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative pathologies such as Alzheimer’s disease (AD). AD is the most prevalent form of dementia, accounting for 60–80% of cases and remains an unmet medical challenge with no cure and just palliative treatments. Recent studies have identified DYRK1A as a promising therapeutic target in AD, given its involvement in multiple biological functions and its alterations correlated with AD progression. In this work, we leverage multiple Artificial Intelligence (AI) tools, including pre- dictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. We construct a dual-target drug discovery framework integrating AI-driven meth- ods with classical techniques to identify novel compounds. An ensemble Quanti- tative Structure-Activity Relationship (QSAR) model is employed for predicting compound affinities, while Directed Message Passing Neural Networks (DMPNN) are used to assess toxicity. In a generative phase, a Hierarchical Graph Genera- tion model (HGG) facilitated the design of potential DYRK1A inhibitors. Promis- ing candidate molecules were refined through classical docking studies, leading to their synthesis and experimental validation. As a result, pyrazolyl-1H -pyrrolo[2,3- b]pyridine was identified as a potent DYRK1A inhibitor, leading to the synthesis of a new derivative series. Enzymatic assays demonstrated nanomolar-level inhibitory activity, while anti-inflammatory and antioxidant properties were confirmed through ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 mi- croglial cells. Pharmacological testing revealed that the mentioned compound and its derivatives exhibit significant DYRK1A inhibition alongside robust antioxidant and anti-inflammatory effects.

AI-driven de-novo design and development of non-toxic DYRK1A inhibitors for Alzheimer’s disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

Discovery of a Novel Chemotype As DYRK1A Inhibitors Against Alzheimer’s Disease: Computational Modeling and Biological Evaluation

Discovery of a novel DYRK1A inhibitor with neuroprotective activity by virtual screening and in vitro biological evaluation

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)

Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Design, Synthesis, and Pharmacological Characterization of Sulfonylurea-Based NLRP3 Inhibitors: Towards an Effective Therapeutic Strategy for Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (hdacs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease

Recent research and development of DYRK1A inhibitors

Design, Synthesis, Biological Evaluation and in Vivo Testing of Dual Phosphodiesterase 5 (PDE5) and Histone Deacetylase 6 (Hdac6)-Selective Inhibitors for the Treatment of Alzheimer's Disease.

Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer's disease: An integrative molecular modeling approach

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents

Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.

Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer’s Disease